Epidermal growth factor receptor signaling in hepatocellular carcinoma: Inflammatory activation and a new intracellular regulatory mechanism

Digestive Diseases

Volumn 30, Issue 5, 2012, Pages 524-531

  Berasain, Carmen ^a   Nicou, Alexandra ^a   Garcia Irigoyen, Oihane ^a   Latasa, M Ujue ^a   Urtasun, Raquel ^a   Elizalde, Maria ^a   Salis, Fabiana ^a   Perugorra, Mara J ^a   Prieto, Jess ^a,b   Recio, Juan A ^c   Corrales, Fernando J ^a   Avila, Matas A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

ADAM17; Amphiregulin; Epidermal growth factor receptor; Mitogen activated protein kinases; Protein methylation

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ARTICLE; DNA SYNTHESIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ADAM PROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HEPATOCYTES; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; METHYLATION; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868153337     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341705     Document Type: Article

References (31)

1. El-Serag HB: Hepatocellular carcinoma. New Engl J Med 2011; 365: 1118-1127.
2. van Malenstein H, van Pelt J, Verslype C: Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer 2011; 47: 1789-1797.
3. Whittaker S, Marais R, Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
4. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-7392.
5. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. New Engl J Med 2008; 359: 1995-2004.
6. Villanueva A, Llovet JM: Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-1426.
7. Berasain C, Castillo J, Prieto J, Avila MA: New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007; 27: 174-185.
8. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaria M, et al: The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med 2009; 234: 713-725.
9. Scheller J, Chalaris A, Garbers C, Rose-John S: ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011; 32: 380-387.
10. Berasain C, Latasa MU, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, et al: Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancers 2011; 3: 2444-2461.
11. Urtsaun R, Latasa MU, Demartis MI, Balzani S, Goñi S, Garcia-Irigoyen O, et al: Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/Yes-associated protein-mediated activation. Hepatology 2011; 54: 2149-2158.
12. Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M, et al: Ectodomain shedding of EGFR ligands an TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest 2010; 120: 2731-2744.
13. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Santamaría M, Lee DC, et al: Novel role for amphiregulin in protection from liver injury. J Biol Chem 2005; 280: 19012-19020.
14. Castillo J, Erroba E, Perugorria MJ, Santamaría M, Lee DC, Prieto J, et al: Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006; 66: 6129-6138.
15. Argast GM, Campbell JS, Brooling JT, Fausto N: Epidermal growth factor receptor transactivation mediates tumor necrosis factorinduced hepatocyte replication. J Biol Chem 2004; 279: 34530-34536.
16. Chokki M, Mitsuhashi H, Kamimura T: Metalloprotease-dependent amphiregulin release mediates tumor necrosis factor-alphainduced IL-8 secretion in the human airway epithelial cell line NCI-H292. Life Sci 2006; 78: 3051-3057.
17. Okada T, Masuda T, Shinkai M, Kariya K, Kataoka T: Post-translational modification of H-Ras is required for activation of, but not for association with, B-Raf. J Biol Chem 1996; 271: 4671-4678.
18. Homberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich H, Westerhoff HV: Control of MAPK signalling: from complexity to what really matters. Oncogene 2005; 24: 5533-5542.
19. Andreu-Perez P, Esteve-Puig R, de Torre-Minguela C, López-Fauqued M, Bech-Serra JJ, Tenbaum S, et al: Protein arginine methyltransferase 5 (PRMT5) regulates ERK1/2 signal transduction amplitude and cell fate through CRAF, Science Signal 2011; 4:ra458.
20. Avila MA, García-Trevijano ER, Lu SC, Corrales FJ, Mato JM: Methylthioadenosine. Int J Biochem Cell Biol 2004; 36: 2125-2130.
21. Pascale RM, Simile MM, Satta G, Seddaiu MA, Daino L, Pinna G, et al: Comparative effects of L-methionine, S-adenosyl-L-methionine and 5-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis. Anticancer Res 1991; 11: 1617-1624.
22. Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, et al: 5-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 2001; 34: 386-394.
23. Hevia H, Varela-Rey M, Corrales FJ, Berasain C, Martinez-Chantar ML, et al: 5-Methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology 2004; 39: 1088-1098.
24. Latasa MU, Gil-Puig C, Fernández-Barrena MG, Rodriguez-Ortigosa CM, Banales J, Urtasun R, et al: Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/-mice. PLoS One 2010; 5:e15690.
25. Sewing A, Wiseman B, Lloyd AC, Land H: High-intensity raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997; 17: 5588-5597.
26. Tsukada Y, Miyazawa K, Kitamura N: High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 2001; 276: 40968-40976.
27. Borrell-Pagès M, Rojo F, Albanell J, Baselga J, Arribas J: TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003; 22: 1114-1124.
28. Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, et al: The ADAMs family of proteases: new biomarkers and therapeutic target for cancer? Clin Proteomics 2011; 8: 9.
29. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG: Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 2010; 16: 3378-3389.
30. Fiorentino L, Vivanti A, Cavalera M, Marzano V, Ronci M, Fabrizi M, et al: Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 2010; 51: 103-110.
31. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A: The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 2011; 1816: 119-131.